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to evaluate safety, pharmacokinetics, and efﬁcacy of
nintedanib vs. sorafenib in European patients with advanced
hepatocellular carcinoma
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A-B. Loembé10 and T. Meyer11
BACKGROUND: This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-
tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efﬁcacy of nintedanib vs. sorafenib in European patients with
unresectable advanced hepatocellular carcinoma (aHCC).
METHODS: Phase I: Patients were stratiﬁed into two groups per baseline aminotransferase/alanine aminotransferase and Child-
Pugh score; MTD was determined. Phase II: Patients were randomised 2:1 to nintedanib (MTD) or sorafenib (400-mg bid) in 28-day
cycles until intolerance or disease progression. Time-to-progression (TTP, primary endpoint), overall survival (OS) and progression-
free survival (PFS) were determined.
RESULTS: Phase-I: no DLTs observed; nintedanib MTD in both groups was 200 mg bid. Phase-II: patients
(N= 93) were randomised to nintedanib (n= 62) or sorafenib (n= 31); TTP was 5.5 vs. 4.6 months (HR= 1.44 [95% CI, 0.81–2.57]),
OS was 11.9 vs. 11.4 months (HR= 0.88 [95% CI, 0.52–1.47]), PFS was 5.3 vs. 3.9 months (HR= 1.35 [95% CI, 0.78–2.34]),
respectively (all medians). Dose intensity and tolerability favoured nintedanib. Fewer patients on nintedanib (87.1%) vs. sorafenib
(96.8%) had drug-related adverse events (AEs) or grade ≥ 3 AEs (67.7% vs. 90.3%), but more patients on nintedanib (28 [45.2%])
had AEs leading to drug discontinuation than did those on sorafenib (7 [22.6%]).
CONCLUSIONS: Nintedanib may have similar efﬁcacy to sorafenib in aHCC.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0051-8
INTRODUCTION
Hepatocellular carcinoma (HCC) is a hyper-vascular tumour1
involving dysregulation of several angiogenic growth factors such
as vascular endothelial growth factor (VEGF),2–4 epidermal growth
factor (EGF),2–4 platelet-derived growth factor (PDGF)2–4 and
ﬁbroblast growth factor (FGF) .5 Sorafenib is a small-molecule
kinase inhibitor of VEGFR, PDGFR, RAF, c-KIT and FLT-3 6, and is the
ﬁrst approved targeted drug worldwide for ﬁrst-line treatment in
advanced HCC. Phase III trials in Western 7 and Asian patients 6
have shown it to signiﬁcantly improve overall survival (OS)
compared with placebo. However, the effect of sorafenib in HCC
is modest, with median survival prolonged by 2–3 months
compared with placebo.6,7
Primary resistance to VEGF-targeted therapy, such as sorafenib,
may occur through a variety of mechanisms,8,9 which may be
overcome by targeting multiple pathways either through
combination regimens or drugs with multiple targets .2
Nintedanib is an oral, small-molecule, triple angiokinase
inhibitor of VEGFR1-3, PDGFRα and β, FGFR1-3, Flt-3, Lck, Lyn
and Src,10 with anti-tumour and anti-angiogenic activity in
preclinical models of HCC .11 Nintedanib is metabolised
in the liver 12, and it is not clear if liver impairment inﬂuences
nintedanib’s metabolism, elimination, tolerability and maximum-
tolerated dose (MTD). Because of this, the published guidelines
for HCC drug development recommend initial phase-I
trials to determine the MTD of a novel agent in the context of
chronic liver disease followed by randomised phase-II trials
with time to progression (TTP) as the primary endpoint .13
Nintedanib for HCC has been developed in accordance with
these guidelines. We report the results of a multicentre,
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open-label, randomised phase-I/II trial that evaluated the MTD,
pharmacokinetics (PK), efﬁcacy and safety of nintedanib vs.
sorafenib in European patients with advanced HCC, who did not
have prior systemic treatment (NCT01004003; 1199.37).
Since different risk factors between Western and Asian
populations, such as incidences of hepatitis B virus (HBV) and
hepatitis C virus (HCV), may inﬂuence responses to targeted
therapies, an identically designed study was conducted in parallel
in Asian patients 14,15 and is reported separately (NCT00987935;
1199.39).
MATERIALS AND METHODS
Study population and eligibility
Key inclusion criteria included patients aged ≥18 years with
advanced HCC not amenable to curative/locoregional therapy and
with ≥1 measurable lesion by Response Evaluation Criteria in Solid
Tumours (RECIST) v1.0 (for phase-II); Eastern Cooperative Oncology
Group (ECOG) performance score (PS) ≤2; Child–Pugh score 5–6
(for phase-II) and alanine/aspartate aminotransferase (ALT/AST)
levels ≤2 times upper limit of normal (ULN) (for phase-II and
phase-I group I; phase-I group II had ALT or AST >2–≤5 times ULN or
Child–Pugh score 7); >4 weeks since most recent local therapy; no
prior systemic therapy for HCC; no history of other malignancy
within the past 3 years; and life expectancy ≥12 weeks. Additional
inclusion criteria are listed in the protocol. The trial protocol was
reviewed by the institutional review board of each participating
centre and conforms to the Helsinki Declaration. All patients
provided written informed consent (ClinicalTrials.gov registration:
NCT01004003).
Study design and treatment
The primary endpoint for phase-I was nintedanib MTD determina-
tion in terms of dose-limiting toxicities (DLTs) occurring during the
MTD determination period (i.e. within the ﬁrst 28 days of therapy).
Pharmacokinetics of nintedanib and its main metabolites BIBF
1202 and BIBF 1202 glucuronide were assessed as an exploratory
endpoint. In view of the observed DLT of transaminitis in the non-
HCC oncology population, patients were stratiﬁed into two groups
according to their ALT/AST and Child–Pugh score at baseline.
Group I contained patients with ALT and AST ≤2 times ULN and
Child–Pugh score 5–6, while group II contained patients with ALT
or AST >2–≤5 times ULN or Child–Pugh score 7. An expansion
cohort of group II patients was started. MTD determination
methods and DLT deﬁnitions for nintedanib appear in supplemen-
tary Data.
Extensive plasma and urine sampling was performed during the
ﬁrst treatment cycle to describe the PK characteristics of
nintedanib and its main metabolites BIBF 1202 and BIBF 1202
glucuronide. Assessments were performed according to the
schedule shown in the protocol. Antiviral treatment was
recommended for patients with chronic HBV infection.
For phase-II, 93 patients were randomised in a 2:1 ratio to
receive nintedanib 200mg bid (n= 62) or sorafenib 400 mg bid (n
= 31) continuously, in 28-day cycles, until intolerable
AEs or disease progression (PD). A randomised design was used
in favour of performing an uncontrolled trial, which was
common at the time the trial was conceived, to permit a
contemporaneous comparison against sorafenib. A 2:1 randomisa-
tion ratio was chosen to generate more data on nintedanib,
especially regarding safety, because data for sorafenib were
already extensively deﬁned. Treatment beyond PD was allowed at
the discretion of the investigator if there was perceived ongoing
clinical beneﬁt.
Randomisation was performed by an integrated response
system using a validated randomisation number-generating
system. Randomisation was stratiﬁed by presence of
extrahepatic spread (EHS) and macrovascular invasion (MVI) (EHS
and/or MVI present vs. both absent). Full details of randomisation,
as well as the dose reduction scheme and trial procedures
and assessments, are shown in the protocol and supplementary
Data.
Study outcomes
The primary endpoints for phase-I and II, respectively, were
determination of the MTD in terms of DLTs and TTP by central
independent review (CIR) according to RECIST v1.0 (which were
the recommended criteria when the protocol was written). Main
secondary endpoints for phase-II were objective tumour
response (OR) according to RECIST v1.0 assessed by CIR, deﬁned
as a best response of complete response (CR) or partial
response (PR); progression-free survival (PFS) assessed by CIR;
and OS. Deﬁnitions and further outcome measures are described
in supplementary Data.
The primary analysis for efﬁcacy and safety was performed after
80% of all planned patients (77% of all included patients) had an
investigator-assessed TTP event.
Safety and tolerability were assessed based on the incidence
and severity of adverse events (AEs) according to CTCAE v3.0,
laboratory abnormalities, physical examination, ECOG PS, vital
signs and electrocardiogram.
Pharmacokinetic sampling
See supplementary Data for details.
Statistical analysis
All analyses were exploratory; any statistical tests were performed
only to provide a statistical framework from which to view the
results and aid planning of further studies. The sample size was
selected to provide a high probability of recording a numerically
positive treatment effect of nintedanib vs. sorafenib. By assuming
median TTPs of 9 months for nintedanib and 6 months for
sorafenib (hazard ratio [HR] 0.67) to represent a clinically
signiﬁcant beneﬁt compared with sorafenib, the probability of
observing any numerically positive treatment effect on TTP (i.e. an
estimated HR for TTP between nintedanib and sorafenib of <1) is
around 93% for 90 patients (2:1 randomisation, 8 months accrual
and 14 months follow-up). See supplementary Data for further
details.
WinNonlin 5.2 (Certara, Princeton, NJ, USA) and SAS Version 9.2
(SAS, Cary, NC, USA) were used for all statistical and PK analyses.
RESULTS
Patient characteristics
Between November 11, 2009 and September 24, 2013, a
total of 32 patients (13 in group I and 19 in group II) were
recruited in phase-I from 4 centres in 2 European countries. Six
patients were screened, but did not enter the trial. Supplementary
Table S1 summarises patient demographics and baseline disease
characteristics; supplementary Table S2 shows the patient
disposition.
For phase-II, of the 132 enroled patients, 93 were randomly
assigned from September 19, 2011 until November 14, 2012, with
all receiving at least one dose of nintedanib (n= 62) or sorafenib
(n= 31; supplementary Figure S1). There were 28 investigational
sites in eight European countries involved in enrolment, of which
26 randomised and treated patients. With the exception of no
evidence of parenchymal liver disease (24.2% in the nintedanib
group vs. 3.2% in the sorafenib group), and HBV-related liver
disease (6.5% in the nintedanib group vs. 22.6% in the sorafenib
group), baseline characteristics were well-balanced between the
two treatment groups. Approximately three quarters of all patients
in both groups were Barcelona Clinic Liver Cancer (BCLC) stage C
(and the remainder mostly stage B). Table 1 summarises baseline
patient characteristics.
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Patient disposition and treatment exposure
The median (range) duration of treatment in phase-I
was 11.3 (0.07–40.5) months in group I vs. 2.14 (0.03–14.1)
months in group II. Median dose intensity for all dose cohorts
was 100%, with the exception of the 200mg cohort in
group I, which was 99.3%. Nintedanib dose reductions
and exposure for phase-I are summarised in supplementary
Table S3.
In phase-II, the median durations of nintedanib and sorafenib
treatments were similar (5.40 months and 5.42 months, respec-
tively). However, the mean treatment duration was nominally
longer in the nintedanib (8.08 months) vs. the sorafenib
(7.28 months) group. Mean dose intensity was also higher for
nintedanib (96.4% in the nintedanib vs. 84.8% in the sorafenib
group).
Determination of MTD
There were no DLTs during the MTD determination period in
either group at any dose up to the prespeciﬁed maximum of 200
mg bid. Thus, the recommended phase-II dose was determined to
be 200mg bid for group I and II patients. DLTs experienced after
the MTD determination period are described in supplementary
Data.
Pharmacokinetics
PK results appear in supplementary Data. In brief, nintedanib
was rapidly absorbed followed by at least biphasic disposition
kinetics (supplementary Figure S2). Maximum plasma
concentrations were achieved around a median of 2 h and the
gMean half-life ranged between 18.3 and 33.0 h (supplementary
Table S4). We observed a trend towards an increased
gMean exposure to nintedanib, BIBF 1202 and BIBF 1202
glucuronide in group II patients compared with those of group I
(supplementary Table S5). However, the range of individual
values strongly overlapped when data from both groups were
compared.
Phase-II efﬁcacy
Primary endpoint. The median TTP according to RECIST v1.0 by
CIR was 5.5 months (95% CI, 3.0–5.6) in the nintedanib group vs.
4.6 months (95% CI, 2.8–7.4) in the sorafenib group; HR= 1.44
(95% CI, 0.81–2.57) (Fig. 1a).
Table 1. Phase-II patient baseline demographics and clinical
characteristicsa
Characteristic Nintedanib, 200
mg bid (n= 62)
Sorafenib, 400
mg bid (n= 31)
Total (N=
93)
Median age, years
(range)
66 (34–86) 64 (28–83) 66 (28–86)
Male sex, n (%) 48 (77.4) 26 (83.9) 74 (79.6)
Race, n (%)
Indian 0 (0.0) 3 (9.7) 3 (3.2)
Taiwanese or
Chinese
0 (0.0) 1 (3.2) 1 (1.1)
Black 0 (0.0) 1 (3.2) 1 (1.1)
Caucasian 57 (91.9) 24 (77.4) 81 (87.1)
Missing 5 (8.1) 2 (6.5) 7 (7.5)
Median time since
diagnosis, months
(range)
2.53 (0–101.4) 2.76 (0.2–77.5) 2.53
(0–101.4)
ECOG PS, n (%)
0 32 (51.6) 18 (58.1) 50 (53.8)
1 28 (45.2) 10 (32.3) 38 (40.9)
2 2 (3.2) 3 (9.7) 5 (5.4)
Child–Pugh score, n (%)
5 42 (67.7) 23 (74.2) 65 (69.9)
6 19 (30.6) 8 (25.8) 27 (29.0)
7b 1 (1.6) 0 (0.0) 1 (1.1)
BCLC stage, n (%)
0 0 (0.0) 1 (3.2) 1 (1.1)
A 1 (1.6) 0 (0.0) 1 (1.1)
B 15 (24.2) 7 (22.6) 22 (23.7)
C 45 (72.6) 23 (74.2) 68 (73.1)
D 1 (1.6) 0 (0.0) 1 (1.1)
MVI, n (%) 22 (35.5) 9 (29.0) 31 (33.3)
EHS, n (%) 40 (64.5) 21 (67.7) 61 (65.6)
Location of EHS, n (%)
Bone 6 (9.7) 5 (16.1) 11 (11.8)
Lung 16 (25.8) 6 (19.4) 22 (23.7)
Lymph 26 (41.9) 9 (29.0) 35 (37.6)
Other 11 (17.7) 7 (22.6) 18 (19.4)
Aetiology of parenchymal liver disease, n (%)
Alcohol related 10 (16.1) 3 (9.7) 13 (14.0)
HBV related 4 (6.5) 7 (22.6) 11 (11.8)
HCV related 13 (21.0) 8 (25.8) 21 (22.6)
HBV+HCV
related
0 (0.0) 0 (0.0) 0 (0.0)
Unknown 23 (37.1) 8 (25.8) 31 (33.3)
Other 12 (19.4) 5 (16.1) 17 (18.3)
Parenchymal liver disease, n (%)
Chronic hepatitis 8 (12.9) 5 (16.1) 13 (14.0)
Steatoﬁbrosis 3 (4.8) 2 (6.5) 5 (5.4)
Cirrhosis 29 (46.8) 20 (64.5) 49 (52.7)
No evidence 15 (24.2) 1 (3.2) 16 (17.2)
Unknown 6 (9.7) 3 (9.7) 9 (9.7)
Other 1 (1.6) 0 (0.0) 1 (1.1)
Type of local therapy, n (%)
Complete surgical
resection
9 (14.5) 3 (9.7) 12 (12.9)
RFA 2 (3.2) 0 (0.0) 2 (2.2)
Table 1 continued
Characteristic Nintedanib, 200
mg bid (n= 62)
Sorafenib, 400
mg bid (n= 31)
Total (N=
93)
PEI 0 (0.0) 0 (0.0) 0 (0.0)
TACE 19 (30.6) 10 (32.3) 29 (31.2)
RT 1 (1.6) 0 (0.0) 1 (1.1)
Other 2 (3.2) 4 (12.9) 6 (6.5)
Stratiﬁcation group, n (%)
I: EHS and/or MVI
present
49 (79.0) 23 (74.2) 72 (77.4)
II: EHS and MVI
both absent
13 (21.0) 8 (25.8) 21 (22.6)
BCLC Barcelona Clinic Liver Cancer, ECOG PS Eastern Cooperative Oncology
Group performance status, EHS extrahepatic spread, HBV hepatitis B, HCV
hepatitis C, MVI macrovascular invasion, PEI percutaneous ethanol
injection, RFA radiofrequency ablation, RT radiotherapy, TACE transarterial
chemoembolisation. aα-fetoprotein (AFP) groups are not shown because
there were too many missing values because a lot of investigative sites
measured activated AFP instead of AFP and there is no transformation of
the values available. bThis patient with a Child–Pugh score of 7 in the
nintedanib group was a protocol deviation
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Time (months)
Events, n (%)
A
B
C
41 (66.1)
5.5
Nintedanib Sorafenib
4.6
18 (58.1)
1.44 (0.81–2.57)Hazard ratio (95% Cl)
Median TTP (months)
Events, n (%) 43 (69.4)
11.9
Nintedanib Sorafenib
11.4
22 (71.0)
0.88 (0.52–1.47)Hazard ratio (95% Cl)
Median OS (months)
Events, n (%) 44 (71.0)
5.3
Nintedanib Sorafenib
3.9
20 (64.5)
1.35 (0.78–2.34)Hazard ratio (95% Cl)
Median PFS (months)
Time (months)
Time (months)
15 16 17 18 19 20 21 22 23 24 25 26 27 28
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Fig. 1 Phase-II Kaplan-Meier curves of (A) time to tumour progression by central independent review assessed according to Response
Evaluation Criteria for Solid Tumours (RECIST) v1.0, (B) overall survival, and (C) progression-free survival by central independent review
assessed according to RECIST v1.0. OS, overall survival; PFS, progression-free survival; TTP, time to progression
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Secondary endpoints. Median OS was 11.9 months (95% CI,
9.2–16.7) in the nintedanib group vs. 11.4 months (95% CI,
6.5–17.0) in the sorafenib group; HR= 0.88 (95% CI, 0.52–1.47;
Fig. 1b).
Median PFS according to RECIST v1.0 by CIR was 5.3 months for
nintedanib (95% CI, 3.0–5.5) vs. 3.9 months for sorafenib (95% CI,
2.8–7.4); HR= 1.35 (95% CI, 0.78–2.34; Fig. 1c). Radiological
response according to RECIST and mRECIST by CIR is summarised
in supplementary Table S6, including the secondary endpoint OR
according to RECIST by CIR. The best percentage change from
baseline in target lesions by CIR for nintedanib and sorafenib are
shown in supplementary Figure S3A and Figure S3B, respectively.
One patient on nintedanib had a PR of 16.0 months duration
according to RECIST by CIR; two patients on sorafenib had a PR
that lasted for 1.9 months and 2.9 months. According to mRECIST
by CIR, there were seven patients on nintedanib and six patients
on sorafenib with a PR. At the cut-off date of July 15, 2014, two
patients on nintedanib and one on sorafenib continued treatment,
with one patient on nintedanib continuing despite progression by
RECIST. This patient continued on treatment beyond progression
for 169 days.
One patient underwent resection following treatment on
nintedanib and remains in complete remission; this was a non-
cirrhotic man who presented with a poorly vascularised HCC that
did not respond to transarterial chemoembolisation. He was then
offered systemic therapy and consented to participate in this
study. Following a long period of disease control and multi-
disciplinary team review, he underwent surgical resection.
Exploratory endpoints. Median TTP as assessed by mRECIST by
CIR in the nintedanib group was 5.5 months (95% CI, 3.1–5.6) vs.
5.5 months in the sorafenib group (95% CI, 2.8–7.4); HR= 1.59
(95% CI, 0.88–2.85) and median TTP by investigator assessment in
the nintedanib group was 5.5 months (95% CI, 3.1–7.4) vs.
3.8 months in the sorafenib group (95% CI, 3.5 to 5.7); HR= 1.05
(95% CI, 0.63–1.76).
Median time to treatment failure was 3.7 months for nintedanib
(95% CI, 2.7–5.5) vs. 3.7 months for sorafenib (95% CI, 2.3–5.7); HR
= 1.27 (95% CI, 0.79–2.02). Subgroup analysis according to
performance status, aetiology of parenchymal liver disease,
baseline hypertension and EHS or MVI suggest no differences in
TTP between the treatment arms, but subgroups were small (data
not shown).
Safety and tolerability
AEs occurring during the phase-I portion are reported in supple-
mentary Data. For the phase-II portion, fewer patients on
nintedanib (87.1%) vs. sorafenib (96.8%) had investigator-
deﬁned drug-related AEs and fewer patients on nintedanib
(67.7%) experienced grade 3 or higher AEs compared with those
on sorafenib (90.3%). AEs occurring during the phase-II portion are
summarised in supplementary Table S7. A total of 25 patients had
AEs leading to dose reduction; 12 (19.4%) in the nintedanib and 13
(41.9%) in the sorafenib group (supplementary Table S8). AEs
leading to drug discontinuation occurred in 28 (45.2%) patients in
the nintedanib group and 7 (22.6%) patients in the sorafenib
group (supplementary Table S8). None of the patients taking
sorafenib had grade 4 or 5 AEs that led to drug discontinuation,
whereas for nintedanib four patients each had grade 4 AEs of
hypertensive crisis, oesophageal varices haemorrhage, fatigue,
asthenia and decreased performance status, plus one patient each
with grade 5 general physical health deterioration and PD that led
to drug discontinuation (none of which were drug related except
for hypertensive crisis, fatigue and asthenia).
AEs associated with VEGF pathway inhibition, and other any-
grade AEs of special interest, included (for nintedanib vs.
sorafenib) speciﬁc liver-related investigations (24.2% vs. 25.8%),
bleeding (29.0% vs. 22.6%), rash (21.0% vs. 38.7%), hypertension
(14.5% vs. 9.7%), cutaneous adverse reactions (4.8% vs. 19.4%),
thromboembolic events (1.6% vs. 12.9%) and gastrointestinal (GI)
perforation (0% vs. 3.2%). No arterial thromboembolic events were
reported. Supplementary Table S9 shows grade ≥3 AEs of special
interest occurring in all the dose cohorts for groups I and II.
Frequently occurring any-grade AEs are summarised in Table 2.
Nausea (48.4% vs. 29.0%), vomiting (38.7% vs. 29.0%) and upper
abdominal pain (25.8% vs. 12.9%) occurred >10% more frequently
with nintedanib compared with sorafenib. Palmar–plantar
Table 2. Most frequently reported (patient level) adverse events by
primary system organ class and preferred term (occurring at any grade
in ≥20% or at grade ≥3 in ≥5% patients in either treatment group)
during the phase-II portion
Adverse event
(SOC and PT)
Nintedanib, 200mg
bid
(n= 62)
Sorafenib, 400mg
bid (n= 31)
All
grades,
n (%)
Grade ≥3,
n (%)
All
grades,
n (%)
Grade
≥3, n (%)
Patients with any adverse
event
62 (100) 42 (67.7) 31 (100) 28 (90.3)
Blood and lymphatic system
disorders
10 (16.1) 5 (8.1) 8 (25.8) 6 (19.4)
Anaemia 6 (9.7) 4 (6.5) 1 (3.2) 1 (3.2)
Thrombocytopenia 2 (3.2) 1 (1.6) 4 (12.9) 3 (9.7)
Gastrointestinal disorders 60 (96.8) 16 (25.8) 29 (93.5) 3 (9.7)
Diarrhoea 44 (71.0) 8 (12.9) 21 (67.7) 1 (3.2)
Nausea 30 (48.4) 1 (1.6) 9 (29.0) 0 (0.0)
Vomiting 24 (38.7) 2 (3.2) 9 (29.0) 0 (0.0)
Abdominal pain 16 (25.8) 0 (0.0) 9 (29.0) 1 (3.2)
Abdominal pain upper 16 (25.8) 0 (0.0) 4 (12.9) 0 (0.0)
General disorders and
administration site
conditions
44 (71.0) 11 (17.7) 21 (67.7) 4 (12.9)
Fatigue 35 (56.5) 7 (11.3) 10 (32.3) 1 (3.2)
Investigations 24 (38.7) 14 (22.6) 17 (54.8) 11 (35.5)
AST increased 11 (17.7) 7 (11.3) 5 (16.1) 1 (3.2)
ALT increased 8 (12.9) 5 (8.1) 3 (9.7) 2 (6.5)
Metabolism and nutrition
disorders
26 (41.9) 4 (6.5) 18 (58.1) 4 (12.9)
Decreased appetite 23 (37.1) 1 (1.6) 13 (41.9) 1 (3.2)
Neoplasms benign,
malignant and unspeciﬁed
(including cysts and polyps)
6 (9.7) 4 (6.5) 4 (12.9) 3 (9.7)
Malignant neoplasm
progression
2 (3.2) 2 (3.2) 3 (9.7) 3 (9.7)
Nervous system disorders 20 (32.3) 7 (11.3) 16 (51.6) 2 (6.5)
Hepatic encephalopathy 5 (8.1) 5 (8.1) 2 (6.5) 1 (3.2)
Lethargy 5 (8.1) 0 (0.0) 8 (25.8) 1 (3.2)
Skin and subcutaneous
tissue disorders
27 (43.5) 2 (3.2) 25 (80.6) 11 (35.5)
Rash 6 (9.7) 0 (0.0) 7 (22.6) 1 (3.2)
Alopecia 3 (4.8) 0 (0.0) 11 (35.5) 0 (0.0)
Palmar–plantar
erythrodysesthesia
syndrome
1 (1.6) 0 (0.0) 11 (35.5) 7 (22.6)
Skin reaction 1 (1.6) 1 (1.6) 3 (9.7) 2 (6.5
ALT alanine aminotransferase, AST aspartate aminotransferase, PT preferred
term, SOC system organ class
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erythrodysesthesia syndrome (35.5% vs. 1.6%), alopecia (35.5% vs.
4.8%) and rash (22.6% vs. 9.7%) were more frequent with
sorafenib compared with nintedanib (Table 2). Grade ≥3
palmar–plantar erythrodysesthesia syndrome occurred in 22.6%
of patients on sorafenib and no patients on nintedanib. AEs of
≥grade 3 occurring in ≥5% of patients are summarised in Table 2.
There were 9 (14.5%) patients on nintedanib and 3 (9.7%) on
sorafenib for whom AEs led to death; this was related to tumour
progression for both drugs for all but one patient in the
nintedanib group who died of interstitial lung disease, for which
a causal relationship to the study drug could not be excluded.
DISCUSSION
This trial showed that nintedanib had antitumour activity and
suggests it had similar efﬁcacy with sorafenib, with a tolerable and
different AE proﬁle, in mainly Caucasian patients with advanced
HCC. The trial design complied with European Association for the
Study of the Liver (EASL) recommendations for HCC trials 16, as
well as those for clinical oncology trials,17 using a randomised
design with an active comparator, and was conducted to determine
whether a high probability of success might be indicated for phase
III trials, rather than to obtain deﬁnitive efﬁcacy information. There
were no pre-planned criteria for progression to a phase III trial,
however. The trial used outcome measures recommended for use in
phase-II trials in HCC,13 and as is common with parallel-group
designs was open-label to better monitor safety on an ongoing basis
and because of the different safety proﬁles and different rules for
dose interruptions and reductions between the nintedanib and
sorafenib groups. A comparable trial with nintedanib in Asian
patients found similar results.14,15
In the phase-I portion, the area under the curve for nintedanib
was broadly comparable to that found in other malignancies.18,19
Nintedanib is metabolised and mainly excreted via the liver 12
such that liver impairment may inﬂuence nintedanib pharmaco-
kinetics. Thus, an exploratory objective of this trial was to describe
the effect of liver function assessed by AST/ALT plasma
concentrations at study baseline (by allocation of patients to
group I or II) and Child–Pugh classiﬁcation on the PK parameters
of nintedanib and its metabolites. Patients were stratiﬁed into two
groups according to baseline liver function and the MTD was
determined to be the same (200mg bid) for both groups with no
signiﬁcant differences in PK parameters. No DLTs occurred during
the MTD determination period. The main DLTs occurring after the
MTD determination period were reversible liver enzyme eleva-
tions. In the phase-II portion of the trial, a higher proportion of
patients in the sorafenib group had severe AEs, drug-related AEs
and AEs leading to dose reductions compared with patients in the
nintedanib group, while a higher proportion of patients in the
nintedanib group (45.2%) had AEs leading to drug discontinuation
compared with those in the sorafenib group (22.6%). Nonetheless,
despite this high rate of nintedanib discontinuation, the duration
of nintedanib treatment was longer than that of sorafenib and the
dose intensity of nintedanib was better, indicating that nintedanib
is reasonably tolerated relative to sorafenib. Approximately a
quarter of patients on nintedanib experienced GI AEs of grade 3 or
higher. This rate was higher than that with sorafenib (9.7%),
underscoring the importance of close clinical monitoring for GI
events, especially given the large impact of GI toxicities on
quality of life. The higher rates of variceal bleeding with
nintedanib, including that leading to drug discontinuation,
suggest baseline endoscopy and control of varices could be a
prudent strategy prior to starting nintedanib. Any-grade drug-
related AEs for sorafenib were generally similar to those in the
SHARP trial,7 although occurring at higher rates in the present trial,
particularly for diarrhoea (67.7% vs. 39% in SHARP) and
palmar–plantar erythrodysesthesia syndrome (35.5% vs. 21% in
SHARP).
Allowing for small patient numbers and wide conﬁdence
intervals, the efﬁcacy in terms of TTP and OS for sorafenib in
this trial is broadly comparable to that reported in the SHARP trial,
which was also conducted in a predominantly European
population.
Limitations of this trial include the fact that correlations
between TTP and PFS with OS still need to be established (a
problem common to all trials in the setting of HCC). Because the
trial was not blinded or powered to detect a signiﬁcant difference
in OS, further blinded, randomised studies would be required to
interrogate potential survival beneﬁts of nintedanib over sorafe-
nib. The patients included in the phase-II portion were untreated,
ﬁrst-line patients. Given the limited beneﬁt of sorafenib in this
setting, documented progressive disease before inclusion could
have been a better way to identify potential differences between
sorafenib and nintedanib. Data on subsequent post-progression
treatment were not mandated, such that its impact on OS could
not be assessed. In contrast with sorafenib, nintedanib has activity
inhibiting FGF receptor signalling. Although the FGF receptor
status of patients was not assessed in this study, future studies
could examine the FGF status of responders to nintedanib.
In conclusion, the current trial suggests nintedanib may have
similar efﬁcacy to sorafenib in patients with advanced HCC, with a
tolerable and different safety proﬁle, but with higher VEGF-related
toxicity. The results suggest that nintedanib could be a suitable
partner for combination studies in HCC.
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